Methods for treating conditions associated with MASP-2 dependent complement activation
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
1. A method for decreasing the likelihood of developing impaired renal function in a subject that presents with bloody diarrhea and tests positive for infection with an enterogenic E. coli , and therefore is at risk for developing hemolytic uremic syndrome (HUS) comprising administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2 dependent complement activation, wherein the MASP-2 inhibitory agent is an anti-MASP-2 monoclonal antibody, or fragment thereof, that specifically binds to a portion of SEQ ID NO: 6.
2. The method of claim 1 , wherein the subject at risk for developing HUS exhibits at least one or more of the symptoms selected from the group consisting of diarrhea, a hematocrit level of less than 30% with smear evidence of intravascular erythrocyte destruction, thrombocytopenia and rising creatinine levels.
3. The method of claim 1 , wherein the subject is infected with an enterogenic E. coli for which the use of antibiotics is contra-indicated.
4. The method of claim 3 , wherein the composition comprising the MASP-2 inhibitory agent is administered to the subject during a first time period in the absence of an antibiotic.
5. The method of claim 4 , wherein the MASP-2 inhibitory agent is administered to the subject during the first time period via an intravenous catheter or other catheter delivery method.
6. The method of claim 5 , further comprising administering the composition comprising the MASP-2 inhibitory agent for a second time period, wherein the composition is administered subcutaneously during the second time period.
7. The method of claim 6 , further comprising administering an antibiotic during the second time period.
8. The method of claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof is an antibody having reduced effector function.
9. The method of claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof is a chimeric antibody.
10. The method of claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof is a humanized antibody.
11. The method of claim 1 , wherein the monoclonal antibody or antigen-binding fragment thereof is a human antibody.